CS244680B2 - Preparation method of gama butyrolactone - Google Patents
Preparation method of gama butyrolactone Download PDFInfo
- Publication number
- CS244680B2 CS244680B2 CS838219A CS821983A CS244680B2 CS 244680 B2 CS244680 B2 CS 244680B2 CS 838219 A CS838219 A CS 838219A CS 821983 A CS821983 A CS 821983A CS 244680 B2 CS244680 B2 CS 244680B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- hal
- group
- hydrogen atom
- compound
- alkyl group
- Prior art date
Links
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 4
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 239000000047 product Substances 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 241000755093 Gaidropsarus vulgaris Species 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- -1 pyridyl acetonitrile Chemical compound 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- PDKVWCYJNKLAGE-UHFFFAOYSA-N 1-(bromomethyl)cyclohexene Chemical compound BrCC1=CCCCC1 PDKVWCYJNKLAGE-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- DBVADBHSJCWFKI-UHFFFAOYSA-N n-(2-chloroethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)CCCl DBVADBHSJCWFKI-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XUPIKCKLBAHVGL-UHFFFAOYSA-N 2-(cyclohexen-1-ylmethyl)-4-[di(propan-2-yl)amino]-2-pyridin-2-ylbutanenitrile Chemical compound C=1C=CC=NC=1C(CCN(C(C)C)C(C)C)(C#N)CC1=CCCCC1 XUPIKCKLBAHVGL-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- UKVQBONVSSLJBB-UHFFFAOYSA-N 2-pyridin-2-ylacetonitrile Chemical compound N#CCC1=CC=CC=N1 UKVQBONVSSLJBB-UHFFFAOYSA-N 0.000 description 1
- LPJLBOSAMLFOSV-UHFFFAOYSA-N 2-pyridin-2-ylbutanenitrile Chemical compound CCC(C#N)C1=CC=CC=N1 LPJLBOSAMLFOSV-UHFFFAOYSA-N 0.000 description 1
- OHXAOPZTJOUYKM-UHFFFAOYSA-N 3-Chloro-2-methylpropene Chemical compound CC(=C)CCl OHXAOPZTJOUYKM-UHFFFAOYSA-N 0.000 description 1
- FMPLFAONIATJEZ-UHFFFAOYSA-N 3-pyridin-2-yloxolan-2-one Chemical compound O=C1OCCC1C1=CC=CC=N1 FMPLFAONIATJEZ-UHFFFAOYSA-N 0.000 description 1
- SCKTYTODRDHXJU-UHFFFAOYSA-N 4-[di(propan-2-yl)amino]-2-pyridin-2-ylbutanenitrile Chemical compound CC(C)N(C(C)C)CCC(C#N)C1=CC=CC=N1 SCKTYTODRDHXJU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RVKFQAJIXCZXQY-CBZIJGRNSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RVKFQAJIXCZXQY-CBZIJGRNSA-N 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- WFYFNYRIQAUMFD-UHFFFAOYSA-N hexane;hypochlorous acid Chemical compound ClO.CCCCCC WFYFNYRIQAUMFD-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- OCBWRNXYRKJHTQ-UHFFFAOYSA-N n-butan-2-yl-n-(2-chloroethyl)butan-2-amine Chemical group CCC(C)N(CCCl)C(C)CC OCBWRNXYRKJHTQ-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS845725A CS244693B2 (cs) | 1983-11-08 | 1984-07-25 | Způsob přípravy derivátů 3-(2-piperidinoetyl)-3-(2-pyridyl)-2- -hexahydrobenzofuranonu |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8218705A FR2535722B1 (fr) | 1982-11-08 | 1982-11-08 | Derives de la g-butyrolactone protecteurs du myocarde presentant une activite antiarythmique, procede pour leur preparation et medicaments en contenant |
Publications (2)
Publication Number | Publication Date |
---|---|
CS821983A2 CS821983A2 (en) | 1985-10-16 |
CS244680B2 true CS244680B2 (en) | 1986-08-14 |
Family
ID=9278999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS838219A CS244680B2 (en) | 1982-11-08 | 1983-11-08 | Preparation method of gama butyrolactone |
Country Status (29)
Country | Link |
---|---|
US (1) | US4542134A (de) |
EP (1) | EP0113600B1 (de) |
JP (1) | JPS59161379A (de) |
KR (1) | KR900006723B1 (de) |
AT (1) | ATE28644T1 (de) |
AU (1) | AU560032B2 (de) |
CA (1) | CA1224467A (de) |
CS (1) | CS244680B2 (de) |
DD (2) | DD220313A5 (de) |
DE (1) | DE3372767D1 (de) |
DK (1) | DK503683A (de) |
ES (1) | ES527092A0 (de) |
FI (1) | FI79538C (de) |
FR (1) | FR2535722B1 (de) |
GR (1) | GR78746B (de) |
HU (1) | HU192825B (de) |
IE (1) | IE56208B1 (de) |
IL (1) | IL70062A (de) |
MA (1) | MA19947A1 (de) |
NO (1) | NO159853C (de) |
NZ (1) | NZ206176A (de) |
OA (1) | OA07581A (de) |
PH (1) | PH19547A (de) |
PL (2) | PL139945B1 (de) |
PT (1) | PT77606B (de) |
SG (1) | SG2389G (de) |
SU (1) | SU1279529A3 (de) |
YU (2) | YU220483A (de) |
ZA (1) | ZA837935B (de) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3714173A (en) * | 1971-07-06 | 1973-01-30 | Smith Kline French Lab | Pyridyl ketipate lactones and derivatives |
FR2467200A1 (fr) * | 1979-10-11 | 1981-04-17 | Clin Midy | Derives du pyrrole actifs sur les troubles du rythme cardiovasculaire |
-
1982
- 1982-11-08 FR FR8218705A patent/FR2535722B1/fr not_active Expired
-
1983
- 1983-10-20 US US06/543,898 patent/US4542134A/en not_active Expired - Fee Related
- 1983-10-25 ZA ZA837935A patent/ZA837935B/xx unknown
- 1983-10-26 IL IL70062A patent/IL70062A/xx unknown
- 1983-10-27 AU AU20639/83A patent/AU560032B2/en not_active Ceased
- 1983-11-03 DK DK503683A patent/DK503683A/da not_active Application Discontinuation
- 1983-11-04 EP EP83402141A patent/EP0113600B1/de not_active Expired
- 1983-11-04 DE DE8383402141T patent/DE3372767D1/de not_active Expired
- 1983-11-04 AT AT83402141T patent/ATE28644T1/de not_active IP Right Cessation
- 1983-11-04 GR GR72873A patent/GR78746B/el unknown
- 1983-11-04 IE IE2580/83A patent/IE56208B1/xx unknown
- 1983-11-04 PT PT77606A patent/PT77606B/pt not_active IP Right Cessation
- 1983-11-05 SU SU3661802A patent/SU1279529A3/ru active
- 1983-11-07 MA MA20167A patent/MA19947A1/fr unknown
- 1983-11-07 DD DD83256412A patent/DD220313A5/de not_active IP Right Cessation
- 1983-11-07 NO NO834053A patent/NO159853C/no unknown
- 1983-11-07 YU YU02204/83A patent/YU220483A/xx unknown
- 1983-11-07 CA CA000440588A patent/CA1224467A/en not_active Expired
- 1983-11-07 NZ NZ206176A patent/NZ206176A/en unknown
- 1983-11-07 FI FI834069A patent/FI79538C/fi not_active IP Right Cessation
- 1983-11-07 KR KR1019830005270A patent/KR900006723B1/ko active IP Right Grant
- 1983-11-07 DD DD83270122A patent/DD231567A5/de not_active IP Right Cessation
- 1983-11-08 CS CS838219A patent/CS244680B2/cs unknown
- 1983-11-08 OA OA58152A patent/OA07581A/xx unknown
- 1983-11-08 PH PH29801A patent/PH19547A/en unknown
- 1983-11-08 JP JP58209771A patent/JPS59161379A/ja active Pending
- 1983-11-08 PL PL1983244461A patent/PL139945B1/pl unknown
- 1983-11-08 PL PL1983249775A patent/PL142949B1/pl unknown
- 1983-11-08 ES ES527092A patent/ES527092A0/es active Granted
- 1983-11-08 HU HU833826A patent/HU192825B/hu not_active IP Right Cessation
-
1985
- 1985-09-12 YU YU01435/85A patent/YU143585A/xx unknown
-
1989
- 1989-01-11 SG SG23/89A patent/SG2389G/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69200685T2 (de) | Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten. | |
EP1339717B1 (de) | Neue carbamat-substituierte pyrazolopyridinderivate | |
EP0934311A2 (de) | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen | |
DE2845499A1 (de) | Alkanoylprolin-derivate und deren homologen, ihre herstellung und verwendung | |
DE2707048A1 (de) | Neue indolizinderivate, verfahren zu deren herstellung, sowie diese enthaltende zusammensetzungen | |
CS244681B2 (en) | Preparation method of 2,6-piperidin-dione-derivatives | |
EP0410208B1 (de) | Chromanderivate | |
DE69528843T2 (de) | Pharmakologisch aktive 2-mercaptobenzimidazolderivate | |
DE3782636T2 (de) | Isoindolin-1-on-derivat und antiarrhythmisches mittel. | |
DD280965A5 (de) | Verfahren zur herstellung von antiarrhythmisch wirkenden mitteln | |
DE2605377A1 (de) | 0-aminooxime, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
CH618439A5 (de) | ||
CS244680B2 (en) | Preparation method of gama butyrolactone | |
DE3802362A1 (de) | Tetrahydrofuranderivate, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel | |
DE3621413A1 (de) | Verwendung carbocyclisch und heterocyclisch annelierter dihydropyridine als cardioprotektive mittel sowie neue heterocyclisch und carbocyclisch anellierte dihydropyridine, verfahren zu deren herstellung und zwischenstufen fuer deren herstellung | |
US4018767A (en) | Anti-arrhythmic agents | |
EP0173933A1 (de) | 1,6-Naphthyridin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
US3655661A (en) | Benzothiadiazole compounds | |
DE69022442T2 (de) | Aminoalkoxyphenyl-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen. | |
DE2320378A1 (de) | Basische ester und verfahren zur herstellung derselben | |
CS244695B2 (cs) | Způsob přípravy derivátů 2,6-piperidíndionu | |
CS244694B2 (cs) | Způsob výroby derivátů 2,6-piperidindionu | |
EP0182271B1 (de) | Neue Nb-quartäre Dibromderivate von Ajmalin, Isoajmalin, Sandwicin und Isosandwicin sowie diese Derivate enthaltende pharmazeutische Zubereitungen und Zwischenprodukte und Verfahren zu ihrer Herstellung | |
AT331246B (de) | Verfahren zur herstellung neuer 1,4-benzodioxan-derivate und ihrer saureadditionssalze | |
KR840001106B1 (ko) | 피리딘 유도체의 제조방법 |